Know Cancer

or
forgot password

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer


Phase 4
18 Years
N/A
Not Enrolling
Male
Cancer of Prostate

Thank you

Trial Information

A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer


Inclusion Criteria:

Patient with Advanced Ca, on stable dose of Lupron or Zoladex

-

Exclusion Criteria:

- Previous exposure to Eligard.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Franklin M Chu, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

San Bernfardino Urological Associates

Authority:

United States: Food and Drug Administration

Study ID:

SBU001

NCT ID:

NCT00220194

Start Date:

April 2003

Completion Date:

June 2005

Related Keywords:

  • Cancer of Prostate
  • Prostatic Neoplasms

Name

Location
San Bernardino Urological Associates Medical Group San Bernardino, California  92404